EU Network Alerts Drug Companies To Legal Repercussions Of Brexit

The EU medicines network is advising drug companies to be proactive in screening their marketing authorization applications to determine whether regulatory action is needed in anticipation of the UK leaving the EU. More than 350 centrally approved products are affected.